大剂量阿托伐他汀序贯治疗对急性非ST段抬高型心肌梗死患者高敏C反应蛋白和短期主要不良心血管事件的影响

发布时间：2018-10-30 11:52

【摘要】：目的探讨大剂量阿托伐他汀序贯治疗对急性非ST段抬高型心肌梗死(NSTEMI)患者高敏C反应蛋白(hs-CRP)和短期主要不良心血管事件(MACE)的影响。方法将2010年9月至2012年4月在我院确诊为NSTEMI并择期PCI患者100例随机分为大剂量阿托伐他汀序贯治疗组(简称序贯治疗组)和阳性对照组。所有患者入院即刻给予80 mg阿托伐他汀钙,随后40 mg/d。序贯治疗组于术前6 h内追加40 mg阿托伐他汀钙,阳性对照组术前未追加阿托伐他汀钙。所有患者分别于PCI术前、术后24 h、48 h测定血脂、hs-CRP,并随访所有患者PCI术后12周内MACE。结果两组患者术后血脂水平与术前相比未见明显变化(P0.05);与术前相比,两组患者术后hs-CRP水平均明显升高(P0.05),序贯治疗组术后hs-CRP水平显著低于阳性对照组(P0.05);两组患者12周内MACE发生率相比差异无统计学意义(4%比6%,P0.05);两组均未见有临床意义的肝酶和肌酶升高,无不良反应发生。结论大剂量阿托伐他汀序贯治疗能一定程度抑制NSTEMI患者PCI术后内皮炎症反应,且安全性良好,但是不能减少12周内MACE。
[Abstract]:Objective to investigate the effects of high dose Atto vastatin sequential therapy on Gao Min C-reactive protein (hs-CRP) and short-term major adverse cardiovascular events (MACE) in patients with acute non-ST segment elevation myocardial infarction (NSTEMI). Methods from September 2010 to April 2012, 100 patients with NSTEMI and selective PCI were randomly divided into two groups: the high-dose Atto vastatin sequential therapy group (Sequential treatment group) and the positive control group. All patients were given 80 mg Atto vastatin calcium immediately after admission and 40 mg/d. later The sequential treatment group received 40 mg Atto vastatin calcium within 6 hours before operation, while the positive control group received no Atto vastatin calcium before operation. Serum lipids were measured before and 24 hours after PCI in all patients. Hs-CRP, was followed up in all patients within 12 weeks after PCI. Results there was no significant change in blood lipid level between the two groups after operation (P0.05). Compared with pre-operation, the level of hs-CRP was significantly higher in both groups (P0.05), and the level of hs-CRP in sequential treatment group was significantly lower than that in positive control group (P0.05). There was no significant difference in the incidence of MACE between the two groups within 12 weeks (4% vs 6% P0.05). Conclusion the high dose Atto vastatin sequential therapy can inhibit the endothelial inflammation after PCI in NSTEMI patients to some extent, and the safety is good, but it can not reduce MACE. within 12 weeks.
【作者单位】：广州医科大学附属第六人民医院心内科;广州医科大学附属第六人民医院放射科;首都医科大学附属北京安贞医院心内科;
【分类号】：R542.22

【相似文献】